Literature DB >> 26472731

Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.

Francisco J Rodríguez-Álvarez1, Eva Jiménez-Mora1, María Caballero1, Beatriz Gallego1, Antonio Chiloeches2, Ma José Toro3.   

Abstract

Somatostatin (SST) is one of the main regulators of thyroid function. It acts by binding to its receptors, which lead to the dissociation of G proteins into Gαi and Gβγ subunits. However, much less is known about the function of Gβγ in thyroid cells. Here, we studied the role of SST and Gβγ dimers released upon SST stimulation on the Ras-ERK1/2 pathway in FTRL-5 thyroid cells. We demonstrate that SST activates Ras through Gi proteins, since SST-induced Ras activation is inhibited by pertussis toxin. Moreover, the specific sequestration of Gβγ dimers decreases Ras-GTP and phosphorylated ERK1/2 levels, and overexpression of Gβγ increases ERK1/2 phosphorylation induced by SST, indicating that Gβγ dimers released after SST treatment mediate activation of Ras and ERK1/2. On the other hand, SST treatment does not modify the expression of the thyroid differentiation marker sodium/iodide symporter (NIS) through ERK1/2 activation. However, SST increases AKT activation and the inhibition of the Src/PI3K/AKT pathway increases NIS levels in SST-treated cells. Thus, we conclude that, in thyroid cells, signalling from SST receptors to ERK1/2 involves a Gβγ-mediated signal acting on a Ras-dependent pathway. Moreover, we demonstrate that SST might regulates NIS expression through a Src/PI3K/AKT-dependent mechanism, but not through ERK1/2 signalling, showing the main role of this hormone in thyroid function.

Entities:  

Keywords:  ERK1/2; Gi proteins; Gβγ; Ras; Somatostatin; Thyroid

Mesh:

Substances:

Year:  2015        PMID: 26472731     DOI: 10.1007/s11010-015-2587-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression.

Authors:  Bibian García; Pilar Santisteban
Journal:  Mol Endocrinol       Date:  2002-02

2.  Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism.

Authors:  L Iacovelli; L Capobianco; L Salvatore; M Sallese; G M D'Ancona; A De Blasi
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

3.  Silencing the expression of multiple Gbeta-subunits eliminates signaling mediated by all four families of G proteins.

Authors:  Jong-Ik Hwang; Sangdun Choi; Iain D C Fraser; Mi Sook Chang; Melvin I Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

4.  Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).

Authors:  T Florio; H Yao; K D Carey; T J Dillon; P J Stork
Journal:  Mol Endocrinol       Date:  1999-01

5.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras.

Authors:  J de Rooij; J L Bos
Journal:  Oncogene       Date:  1997-02-06       Impact factor: 9.867

6.  Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits.

Authors:  P Crespo; N Xu; W F Simonds; J S Gutkind
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

7.  Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells.

Authors:  Yu-Yu Liu; Xiaoli Zhang; Matthew D Ringel; Sissy M Jhiang
Journal:  Endocr Relat Cancer       Date:  2012-05-03       Impact factor: 5.678

8.  β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway.

Authors:  Marie Vidal; Thomas Wieland; Martin J Lohse; Kristina Lorenz
Journal:  Cardiovasc Res       Date:  2012-07-27       Impact factor: 10.787

9.  Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells.

Authors:  Miguel A Zaballos; Bibian Garcia; Pilar Santisteban
Journal:  Mol Endocrinol       Date:  2008-01-17

Review 10.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

View more
  2 in total

1.  Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

Authors:  Taofeek K Owonikoko; Guojing Zhang; Shenila B Lallani; Zhengjia Chen; Deborah E Martinson; Fadlo R Khuri; Sagar Lonial; Adam Marcus; Shi-Yong Sun
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

2.  GNG2 acts as a tumor suppressor in breast cancer through stimulating MRAS signaling.

Authors:  Anjiang Zhao; Dan Li; Xiongmin Mao; Mengliu Yang; Wuquan Deng; Wenjing Hu; Chen Chen; Gangyi Yang; Ling Li
Journal:  Cell Death Dis       Date:  2022-03-23       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.